ChemExpress Expands ADC Manufacturing with New GMP Site

• ChemExpress has opened a new 56,000m² GMP facility in Chongqing, China, dedicated to ADC/XDC contract development and manufacturing services.

• The site offers end-to-end solutions, including antibody manufacturing, payload-linker production, bioconjugation, and drug product manufacturing.

ChemExpress has announced the official opening of its new GMP manufacturing site, Chongqing Haoyuan Biopharmaceutical Co., Ltd., in March 2025. The 56,000m² facility, located in Chongqing International Biological Park, Banan District, is designed to provide comprehensive contract development and manufacturing (CDMO) services for antibody-drug conjugates (ADCs) and other bioconjugates (XDCs).

The new site expands ChemExpress’ capabilities with a fully integrated ADC/XDC solution, covering antibody drug substance (DS) GMP manufacturing with an 8,000-litre annual capacity, payload-linker GMP production with over 80 payloads and 400 linkers available, and ADC bioconjugation techniques such as cysteine, lysine, and enzyme conjugations. Additionally, the facility supports ADC drug product (DP) manufacturing, with a production capacity of up to 2 million bottles per year.

With this expansion, ChemExpress aims to enhance its position in the ADC/XDC market, supporting global biopharmaceutical companies and drug developers in advancing next-generation therapeutics. “The launch of the Chongqing site marks a significant milestone in ChemExpress’ commitment to advancing ADC/XDC therapeutics,” the company stated.